Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Instead, this investigational medicine mimics the activity of two ... AbbVie's two immunology medicines, Skyrizi and Rinvoq, were the stars of the show, once again. Management continues to expect ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
AbbVie Inc. (NYSE:ABBV) showed positive top-line growth from its immunosuppressive drugs, Skyrizi and Rinvoq ... Innovative Medicine and MedTech. Its Innovative Medicine segment encompasses ...
and AbbVie’s recently-approved Skyrizi (risankizumab) – are already shifting treatment away from older TNF blockers. That is down to higher skin clearance rates and also because they don’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback